株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

持続血糖モニタリング(CGM)の世界市場 - 成長、動向、予測(2019年~2024年)

Continuous Glucose Monitoring (CGM) Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 808267
出版日 ページ情報 英文 75 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
持続血糖モニタリング(CGM)の世界市場 - 成長、動向、予測(2019年~2024年) Continuous Glucose Monitoring (CGM) Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 75 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

当レポートでは、世界の持続血糖モニタリング(CGM)市場を調査し、市場の概要、コンポーネント・地域別の市場規模の推移と予測、市場の成長要因および阻害要因、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査結果
  • 前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • コンポーネント別
    • センサー
    • 受信機
  • 地域別
    • 北米
    • 欧州
    • ラテンアメリカ
    • アジア太平洋地域
    • 中東・アフリカ

第6章 市場指標

  • 1型糖尿病の患者の推移と予測
  • 2型糖尿病の患者の推移と予測

第7章 競合情勢

  • 企業プロフィール
    • Abbott Diabetes Care
    • Dexcom
    • Medtronic
  • 企業シェア分析
    • Abbott Diabetes Care
    • Dexcom
    • Medtronic
    • その他

第8章 市場機会と将来展望

目次
Product Code: 65527

Market Overview

As per WHO data, approximately half of all mortality can be associated with high blood glucose levels, which occur before the age of 70 years.

WHO also expects diabetes to be the seventh-leading cause of mortality by 2030. For patients reliant on insulin pumps or daily insulin injections, the CGM establishes itself to be an instrumental tool, which helps in the enhancement of glycemic balance without increasing the danger of fatal hypoglycemia.

As studied in several clinical trials, diabetic patients with Type 1 diabetes mellitus (T1DM) have been shown to have better glycemic control, in comparison to when glucometer is used for routine self-monitoring blood glucose.

The trend follows in children, as well as those who use a CGM on a regular basis. The results in these children show better-glycosylated hemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia.

The current CGM models approved administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in the interstitial fluid.

Scope of the Report

By the component, the market has been segmented into sensors and receivers.

CGM devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays.

Most of the real-time CGMs can offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose.

Key Market Trends - Complete Information about Blood Glucose Patterns and Trends

CGMs are used to provide a further descriptive representation of blood glucose patterns and tendencies than what can be achieved by conventional routine checking of glucose levels at set intervals.

The current CGM devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays.

Most of the real-time CGMs have the capability to offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, in order to facilitate timely management of blood glucose.

This factor, along with the fact that CGM devices are becoming cheaper with the advent of new technologies, like cell phone integration, is likely to drive the steady growth of the CGM market during the forecast period.

North America will Maintain Dominance in the Market

In North America, the United States accounted for close to 97% of the market value in 2017. By 2019, the continuous glucose monitoring market in the United States is expected to be valued at USD 1175.5 million.

The United States also accounts for the highest CAGR of 13.2%. It is imperative that the CGM devices be used alongside insulin pumps. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold will also follow.

Competitive Landscape

A major share of the market is held by CGM manufacturers that are concomitant with strategy-based M&A operations and are constantly entering new markets to generate new revenue streams and to boost existing ones.

These measures taken by the market players will ensure a competitive market place, therefore, forcing the companies to experiment with more new technologies, in order to ensure uniqueness in their products.

Also, one of the implications of the competition in the market is that it will ensure a constant decrease in the average selling price of the CGM units produced.

For instance, in December 2017, Abbott's new FreeStyle Libre Flash Glucose Monitoring System was approved, which is the first continuous blood sugar monitor for diabetics that does not need backup finger prick tests, Abbott has also priced the new device substantially lower than its competitors, which will help the company to strengthen its position in the CGM market during the forecast period.

In January 2016, Ypsomed AG appointed TD Pharmaceutical (Tonghua Dongbau Pharmaceutical) as the exclusive distributor for its range of products in China; hence, reinforcing their pre-existing partnership.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation

  • 5.1 Continuous Blood Glucose Monitoring
    • 5.1.1 By Component (Value and Volume, 2012 - 2024)
      • 5.1.1.1 Sensors
      • 5.1.1.2 Receivers
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012 - 2024)
      • 5.2.1.2 Canada (Value and Volume, 2012 - 2024)
      • 5.2.1.3 Rest of North America (Value and Volume, 2012 - 2024)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume, 2012 - 2024)
      • 5.2.2.2 Germany (Value and Volume, 2012 - 2024)
      • 5.2.2.3 Italy (Value and Volume, 2012 - 2024)
      • 5.2.2.4 Spain (Value and Volume, 2012 - 2024)
      • 5.2.2.5 United Kingdom (Value and Volume, 2012 - 2024)
      • 5.2.2.6 Russia (Value and Volume, 2012 - 2024)
      • 5.2.2.7 Rest of Europe (Value and Volume, 2012 - 2024)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume, 2012 - 2024)
      • 5.2.3.2 Brazil (Value and Volume, 2012 - 2024)
      • 5.2.3.3 Rest of Latin America (Value and Volume, 2012 - 2024)
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume, 2012 - 2024)
      • 5.2.4.2 South Korea (Value and Volume, 2012 - 2024)
      • 5.2.4.3 China (Value and Volume, 2012 - 2024)
      • 5.2.4.4 India (Value and Volume, 2012 - 2024)
      • 5.2.4.5 Australia (Value and Volume, 2012 - 2024)
      • 5.2.4.6 Vietnam (Value and Volume, 2012 - 2024)
      • 5.2.4.7 Malaysia (Value and Volume, 2012 - 2024)
      • 5.2.4.8 Indonesia (Value and Volume, 2012 - 2024)
      • 5.2.4.9 Philippines (Value and Volume, 2012 - 2024)
      • 5.2.4.10 Thailand (Value and Volume, 2012 - 2024)
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2024)
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume, 2012 - 2024)
      • 5.2.5.2 Iran (Value and Volume, 2012 - 2024)
      • 5.2.5.3 Egypt (Value and Volume, 2012 - 2024)
      • 5.2.5.4 Oman (Value and Volume, 2012 - 2024)
      • 5.2.5.5 South Africa (Value and Volume, 2012 - 2024)
      • 5.2.5.6 Rest of Middle & Africa (Value and Volume, 2012 - 2024)

6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2024)
  • 6.2 Type 2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Dexcom
    • 7.1.3 Medtronic
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Abbott Diabetes Care
    • 7.2.2 Dexcom
    • 7.2.3 Medtronic
    • 7.2.4 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS